Your search for tofacitinib returned 2 results

Pfizer announced results from two of its Phase 3 studies, ORAL Standard and Oral Step, of tofacitinib (CP-690,550) for the treatment of active rheumatoid arthritis.

Pfizer announced results from its Phase 3 study of tofacitinib, formerly known as tasocitinib, for the treatment of patients with rheumatoid arthritis (RA).